MASP2 and cancer: Clinical data shows complement activation in CRC patients [56] and Ytting et al. have found that MASP-2, a protease responsible for activating the complement cascade, has an independent prognostic value in CRC patients, and that a high level of MASP-2 significantly correlates with recurrent cancer [57].